PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 7:56 AM ET

Sponsor Check › Person

WH
No photo found yet (own website and image search run after this page is viewed)

Wende Hutton

Named as an officer, director or promoter on SEC Form D filings · CA, MA, WA, TX · Apr 7, 2009 → Jun 17, 2026

18deals (issuers)
$430.4Mreported sold
333investors
63Form D filings
2009–2026years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:16 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Wende Hutton is listed as a director on 63 SEC Form D filings by 18 issuers between Apr 2009 and Jun 2026. Largest by amount reported sold: Dermira, Inc. (Menlo Park, CA — other health care — 2012–2014; $51M reported sold to 15 investors), OncoResponse, Inc (Houston, TX — biotechnology — 2015–2025; $40.6M reported sold to 14 investors), REVISION OPTICS INC (Lake Forest, CA — other technology — 2010–2016; $39.7M reported sold to 13 investors), Antiva Biosciences, Inc. (Redwood City, CA — biotechnology — 2015–2024; $38.5M reported sold to 26 investors), CHRONO THERAPEUTICS INC. (Hayward, CA — other health care — 2014–2016; $37.6M reported sold to 31 investors) and 13 more (all listed below).

What this means That is a lot of deals — 18 separate companies raised money with this person listed as director, over about 17 years. Across those companies the filings report $430.4M sold in total.

Listed alongside Clifford Stocks (11 shared filings), Steven Gillis (11 shared filings), Russ Hawkinson (10 shared filings), Christopher Mirabelli (7 shared filings), Kristine Swiderek (6 shared filings) and 179 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Wende. Each name links to their own page.

1 of the issuers belongs to the sponsor group Venbio (7 issuers, $1.97B reported sold, 2010–2024).

What this means A sponsor group is one team that sets up a new company for each deal. Venbio has 7 companies on file and $1.97B reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared the newest 50 of 63 public filings for Wende Hutton and found 12 differences, 3 worth asking the sponsor about: 34% of the money raised went to insiders; Wende Hutton appears on 5 deals that stopped filing before reaching their target; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Wende Hutton has not run yet — it is joining a line of 29,113 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:16 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Wende Hutton..

State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:16 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

12 differences found between the filings for Wende Hutton — 3 worth asking about (compared the newest 50 of 63 filings on Oct 24, 2026; older filings not covered)

Note · Feb 28, 2013 – Aug 25, 2016

Bankruptcy case: Christopher M. Mirabelli and Dana M. Mirabelli — filed Feb 28, 2013

United States Bankruptcy Court, D. New Jersey docket "Christopher M. Mirabelli and Dana M. Mirabelli" filed Feb 28, 2013, closed Aug 25, 2016. Christopher Mirabelli (listed on the same filings) is listed as Debtor ("Christopher M. Mirabelli and Dana M. Mirabelli"). Our match estimate: 80%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, D. New Jersey ↗Christopher Mirabelli — PartnerFacts page ↗
Sources
Note · Jul 2, 2002 – Feb 12, 2003

Bankruptcy case: Dipierro & Assocites Inc — filed Jul 2, 2002

United States Bankruptcy Court, C.D. California docket "Dipierro & Assocites Inc" filed Jul 2, 2002, closed Feb 12, 2003. GUY DIPIERRO (listed on the same filings) is listed as Debtor ("Dipierro & Assocites Inc"). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, C.D. California ↗GUY DIPIERRO — PartnerFacts page ↗
Sources
Worth asking · May 12, 2023

34% of the money raised went to insiders — OncoResponse, Inc

The May 12, 2023 Form D reports $13,915,153 sold and $4,800,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate). Issuer's note: "The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-m".

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · May 12, 2023 ↗OncoResponse, Inc — PartnerFacts page ↗
Sources
Worth asking · Dec 28, 2012 – Aug 2, 2024

Wende Hutton appears on 5 deals that stopped filing before reaching their target

Glooko, Inc. (last filing Aug 2, 2024; $30,000,000 sold of $124,000,000); Stargazer Pharmaceuticals, Inc. (last filing May 13, 2020; $28,461,471 sold of $62,183,282); Butterfly Health, Inc. (last filing May 8, 2015; $5,556,575 sold of $15,383,300); ALDEA Pharmaceuticals, Inc. (last filing Aug 25, 2014; $11,380,718 sold of $24,058,143); Labrys Biologics, Inc. (last filing Dec 28, 2012; $14,588,234 sold of $30,999,997). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Glooko, Inc. — PartnerFacts page ↗Stargazer Pharmaceuticals, Inc. — PartnerFacts page ↗Butterfly Health, Inc. — PartnerFacts page ↗ALDEA Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Worth asking · Aug 4, 2011 – Nov 15, 2021

6 Form Ds were filed more than 15 days after the first sale

Form D filed 140 days after the first sale — Theraclone Sciences, Inc. · Form D filed 77 days after the first sale — Dermira, Inc. · Form D filed 405 days after the first sale — Dermira, Inc. · Form D filed 18 days after the first sale — Alchera Inc · Form D filed 46 days after the first sale — Dermira, Inc. · and 1 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Jul 29, 2013 ↗Theraclone Sciences, Inc. — PartnerFacts page ↗Form D · Jun 13, 2013 ↗Dermira, Inc. — PartnerFacts page ↗
Sources
Note · Aug 4, 2011 – May 6, 2025

28 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — OncoResponse, Inc (latest filing May 6, 2025) · No amendment in the last 12 months on an offering that may still be open — Antiva Biosciences, Inc. (latest filing Oct 11, 2024) · No amendment in the last 12 months on an offering that may still be open — Hyalex Orthopaedics, Inc. (latest filing Oct 2, 2024) · No amendment in the last 12 months on an offering that may still be open — OncoResponse, Inc (latest filing May 12, 2023) · No amendment in the last 12 months on an offering that may still be open — Alchera Inc (latest filing Nov 15, 2021) · and 23 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · May 6, 2025 ↗OncoResponse, Inc — PartnerFacts page ↗Form D/A · Oct 11, 2024 ↗Antiva Biosciences, Inc. — PartnerFacts page ↗
Sources
Note · Jul 25, 2011 – Jul 9, 2021

10 offerings changed their target amount between filings

Offering amount changed between filings — Hyalex Orthopaedics, Inc. · Offering amount changed between filings — Stargazer Pharmaceuticals, Inc. · Offering amount changed between filings — Hyalex Orthopaedics, Inc. · Offering amount changed between filings — OncoResponse, Inc · Offering amount changed between filings — Transcend Medical Inc · and 5 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D/A (earlier) · Mar 29, 2019 ↗Form D/A (later) · Jul 9, 2021 ↗Hyalex Orthopaedics, Inc. — PartnerFacts page ↗Form D (earlier) · Apr 16, 2018 ↗
Sources
Note · Apr 2, 2014 – Jan 5, 2015

Minimum investment changed between filings — Transcend Medical Inc

The Apr 2, 2014 filing lists a minimum of $0; the Jan 5, 2015 Form D/A lists $1.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Apr 2, 2014 ↗Form D/A (later) · Jan 5, 2015 ↗Transcend Medical Inc — PartnerFacts page ↗
Sources
Note · Jul 25, 2011 – Sep 30, 2014

Wende Hutton is written 2 different ways on the filings

listed as "Wende Hutton" on 51 filings (from Jul 25, 2011), and "Wende S. Hutton" on 2 filings (from Sep 30, 2014).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jul 25, 2011 ↗Form D · Sep 30, 2014 ↗Wende Hutton — PartnerFacts page ↗
Sources
Note · Mar 3, 2015 – Nov 19, 2015

Same name, different state: "Wende Hutton" (OH) is a separate record

This page covers filings where the address state is CA or MA or WA or TX. A separate record, "Wende Hutton" with address state OH, is listed on 3 filings — most recently by Minimally Invasive Devices Inc. (Nov 19, 2015). Both records have filings in the same period (Mar 3, 2015 to Nov 19, 2015).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Wende Hutton (OH) — PartnerFacts page ↗Form D/A · Nov 19, 2015 ↗Minimally Invasive Devices Inc. — PartnerFacts page ↗Wende Hutton (CA,MA,WA,TX) — this page ↗
Sources
Note · May 8, 2012 – May 6, 2025

10 address changes between filings

Address moved from Seattle, WA to Houston, TX — OncoResponse, Inc · Address moved from Brisbane, CA to Redwood City, CA — Antiva Biosciences, Inc. · Address moved from Cambridge, MA to Dedham, MA — Qlaris Bio, Inc. · Address moved from South San Francisco, CA to Brisbane, CA — Antiva Biosciences, Inc. · Address moved from Menlo Park, CA to Seattle, WA — OncoResponse, Inc · and 5 more

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · May 12, 2023 ↗Form D · May 6, 2025 ↗OncoResponse, Inc — PartnerFacts page ↗Form D · May 5, 2023 ↗
Sources
Note · Jul 25, 2011 – Jun 17, 2026

Wende Hutton is listed with 4 different address states: CA, MA, WA, TX

CA on 42 filings (Jul 25, 2011 to Jun 17, 2026); MA on 7 filings (Jun 13, 2014 to Oct 2, 2024); WA on 3 filings (Oct 15, 2015 to Mar 23, 2017); TX on 1 filing (May 6, 2025).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jul 25, 2011 ↗Form D · Jun 13, 2014 ↗Form D · Oct 15, 2015 ↗Form D · May 6, 2025 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 63 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

0 of 48 offerings report sales commissions; 2 report finder's fees totalling $2,150,345; 9 report proceeds to related persons totalling $9,469,028. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jun 17, 2026 D
Qlaris Bio, Inc.
File 021-587687
$0$0$0
No amounts other than ordinary course employment compensation is being paid to officers and directors.
None listed on this filingEDGAR ↗
Nov 17, 2025 D
Qlaris Bio, Inc.
File 021-564231
$0$0$0
No amounts other than ordinary course employment compensation is being paid to officers and directors.
None listed on this filingEDGAR ↗
May 6, 2025 D
OncoResponse, Inc
File 021-545368
$0$0$0None listed on this filingEDGAR ↗
Oct 11, 2024 D/A
Antiva Biosciences, Inc.
File 021-480968
$0$0$0None listed on this filingEDGAR ↗
Oct 2, 2024 D
Hyalex Orthopaedics, Inc.
File 021-525614
$0$0$0None listed on this filingEDGAR ↗
Aug 2, 2024 D
Glooko, Inc.
File 021-520416
$0$0$0None listed on this filingEDGAR ↗
Apr 22, 2024 D
Qlaris Bio, Inc.
File 021-511175
$0$0$0
No amounts other than ordinary course employment compensation is being paid to officers and directors.
None listed on this filingEDGAR ↗
Aug 18, 2023 D
Glooko, Inc.
File 021-490085
$0$0$0None listed on this filingEDGAR ↗
May 12, 2023 D
OncoResponse, Inc
File 021-481584
$0$0$4,800,000 (est.)
The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.
None listed on this filingEDGAR ↗
Nov 15, 2021 D
Alchera Inc
File 021-420973
$0$0$250,000 (est.)
Ordinary salary for two executive officers; no cash compensation for any members of the Board.
None listed on this filingEDGAR ↗
Nov 3, 2021 D
Antiva Biosciences, Inc.
File 021-419677
$0$0$0None listed on this filingEDGAR ↗
Jul 9, 2021 D/A
Hyalex Orthopaedics, Inc.
File 021-287679
$0$0$0None listed on this filingEDGAR ↗
Mar 31, 2021 D
OncoResponse, Inc
File 021-394093
$0$0$1,400,000 (est.)
The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.
None listed on this filingEDGAR ↗
Mar 17, 2021 D
Glooko, Inc.
File 021-392587
$0$0$0None listed on this filingEDGAR ↗
May 13, 2020 D/A
Stargazer Pharmaceuticals, Inc.
File 021-310231
$0$0$0None listed on this filingEDGAR ↗
Aug 28, 2019 D
Qlaris Bio, Inc.
File 021-347553
$0$0$0None listed on this filingEDGAR ↗
Sep 6, 2018 D
OncoResponse, Inc
File 021-320707
$0$0$1,200,000 (est.)
The amount reflects payments of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.
None listed on this filingEDGAR ↗
Jul 19, 2018 D
Antiva Biosciences, Inc.
File 021-317252
$0$0$0N/A no CRD number reportedEDGAR ↗
Mar 23, 2017 D/A
OncoResponse, Inc
File 021-249440
$0$0$0None listed on this filingEDGAR ↗
Nov 10, 2016 D
REVISION OPTICS INC
File 021-274296
$0$0$0 (est.)None listed on this filingEDGAR ↗
Sep 9, 2016 D
CHRONO THERAPEUTICS INC.
File 021-270385
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Jun 11, 2015 D
Antiva Biosciences, Inc.
File 021-241545
$0$0$18,288None listed on this filingEDGAR ↗
May 8, 2015 D
Butterfly Health, Inc.
File 021-239429
$0$0$0None listed on this filingEDGAR ↗
May 7, 2015 D
Theraclone Sciences, Inc.
File 021-239360
$0$0$0None listed on this filingEDGAR ↗
Jan 5, 2015 D/A
Transcend Medical Inc
File 021-214739
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2014 D
Dermira, Inc.
File 021-225481
$0$1,950,345$0Leerink Partners LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Aug 25, 2014 D
ALDEA Pharmaceuticals, Inc.
File 021-223549
$0$0$0 (est.)None listed on this filingEDGAR ↗
Jun 13, 2014 D
CHRONO THERAPEUTICS INC.
File 021-219207
$0$0$0Leerink Partners LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Nov 18, 2013 D/A
ALDEA Pharmaceuticals, Inc.
File 021-166855
$0$0$740None listed on this filingEDGAR ↗
Sep 4, 2013 D/A
Butterfly Health, Inc.
File 021-200459
$0$0$0None listed on this filingEDGAR ↗
Aug 2, 2013 D
REVISION OPTICS INC
File 021-200634
$0$0$600,000 (est.)None listed on this filingEDGAR ↗
Jul 29, 2013 D/A
Theraclone Sciences, Inc.
File 021-200360
$0$0$0None listed on this filingEDGAR ↗
Jun 13, 2013 D
Dermira, Inc.
File 021-197911
$0$0$0None listed on this filingEDGAR ↗
Apr 16, 2013 D
REVISION OPTICS INC
File 021-195083
$0$0$600,000 (est.)None listed on this filingEDGAR ↗
Mar 26, 2013 D
Theraclone Sciences, Inc.
File 021-193896
$0$0$0None listed on this filingEDGAR ↗
Dec 28, 2012 D
Labrys Biologics, Inc.
File 021-189143
$0$0$0None listed on this filingEDGAR ↗
Sep 12, 2012 D
Dermira, Inc.
File 021-184023
$0$0$0None listed on this filingEDGAR ↗
Sep 6, 2012 D
Butterfly Health, Inc.
File 021-183709
$0$0$0None listed on this filingEDGAR ↗
Feb 23, 2012 D/A
Altheos, Inc.
File 021-163369
$0$0$0None listed on this filingEDGAR ↗
Nov 23, 2011 D/A
Theraclone Sciences, Inc.
File 021-165656
$0$0$0None listed on this filingEDGAR ↗
Jul 14, 2011 D
Transcend Medical Inc
File 021-162881
$0$0$0None listed on this filingEDGAR ↗
Apr 14, 2011 D
Calibra Medical, Inc.
File 021-158369
$0$0$0None listed on this filingEDGAR ↗
Mar 4, 2011 D
Calibra Medical, Inc.
File 021-156203
$0$0$0None listed on this filingEDGAR ↗
May 18, 2010 D
REVISION OPTICS INC
File 021-142195
$0$0$600,000 (est.)None listed on this filingEDGAR ↗
Mar 17, 2010 D
Theraclone Sciences, Inc.
File 021-71676
$0$0$0None listed on this filingEDGAR ↗
Feb 22, 2010 D
Calibra Medical, Inc.
File 021-76805
$0$0$0None listed on this filingEDGAR ↗
Aug 20, 2009 D/A
Transcend Medical Inc
File 021-96106
$0$0$0None listed on this filingEDGAR ↗
Apr 7, 2009 D
Apieron Inc
File 021-105860
$0$200,000$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 18

Every issuer that named Wende Hutton on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

QB
Biotechnology

Qlaris Bio, Inc.

Dedham, MA · Aug 28, 2019 → Jun 17, 2026 · 4 filings
  • Jun 17, 2026 · D · $3,946,659 sold of $3,946,659 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 17, 2025 · D · $5,641,600 sold of $5,641,600 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 22, 2024 · D · $24,032,554 sold of $24,032,554 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 28, 2019 · D · $8,164,654 sold of $27,325,180 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $24M from 8 investors (100% of the $3.95M target) as of the latest filing. Wende is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

O
Biotechnology

OncoResponse, Inc

Houston, TX · Oct 15, 2015 → May 6, 2025 · 7 filings
  • May 6, 2025 · D · $5,999,138 sold of Indefinite · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 12, 2023 · D · $13,915,153 sold of $40,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 31, 2021 · D · $40,625,995 sold of $60,000,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 6, 2018 · D · $18,999,999 sold of $39,999,995 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 23, 2017 · D/A · $29,499,000 sold of $34,044,454 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 26, 2016 · D/A · $19,499,000 sold of $28,224,448 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 15, 2015 · D · $16,499,000 sold of $28,224,448 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $40.6M from 14 investors as of the latest filing. Wende is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Antiva Biosciences, Inc.

Redwood City, CA · Jun 11, 2015 → Oct 11, 2024 · 5 filings
  • Oct 11, 2024 · D/A · $38,535,985 sold of $52,999,990 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 5, 2023 · D · $26,565,771 sold of $52,999,990 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 3, 2021 · D · $15,639,364 sold of $31,001,635 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 19, 2018 · D · $15,000,000 sold of $15,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 11, 2015 · D · $8,907,483 sold of $15,969,973 · 26 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $38.5M from 26 investors (73% of the $53M target) as of the latest filing. Wende is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

HO
Other Health Care

Hyalex Orthopaedics, Inc.

Lexington, MA · May 30, 2017 → Oct 2, 2024 · 4 filings
  • Oct 2, 2024 · D · $14,874,761 sold of $18,124,761 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 9, 2021 · D/A · $30,604,063 sold of $34,866,680 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 29, 2019 · D/A · $15,531,398 sold of $33,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 30, 2017 · D · $9,305,398 sold of $16,390,013 · 19 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $30.6M from 22 investors (100% of the $18.1M target) as of the latest filing. Wende is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

G
Other Health Care

Glooko, Inc.

Palo Alto, CA · Mar 17, 2021 → Aug 2, 2024 · 3 filings
  • Aug 2, 2024 · D · $0 sold of $124,000,000 · 0 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 18, 2023 · D · $0 sold of $67,000,000 · 0 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 17, 2021 · D · $30,000,000 sold of $35,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $30M from 11 investors (24% of the $124M target) as of the latest filing. Wende is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Other Health Care

Alchera Inc

Walnut Creek, CA · Nov 15, 2021
  • Nov 15, 2021 · D · $5,202,580 sold of Indefinite · 56 investors · min. $2,000 · role: Director EDGAR ↗

Raised $5.7M from 60 investors as of the latest filing. Wende is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(c) (171 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SP
Pharmaceuticals

Stargazer Pharmaceuticals, Inc.

Boston, MA · May 13, 2020
  • May 13, 2020 · D/A · $28,461,471 sold of $62,183,282 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $28.5M from 9 investors (46% of the $62.2M target) as of the latest filing. Wende is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RO
Other Technology

REVISION OPTICS INC

Lake Forest, CA · May 18, 2010 → Nov 10, 2016 · 4 filings
  • Nov 10, 2016 · D · $31,973,690 sold of $45,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 2, 2013 · D · $39,699,993 sold of $39,699,993 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 16, 2013 · D · $14,999,998 sold of $14,999,998 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 18, 2010 · D · $35,000,000 sold of $35,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $39.7M from 13 investors (88% of the $45M target) as of the latest filing. Wende is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Other Health Care

CHRONO THERAPEUTICS INC.

Hayward, CA · Jun 13, 2014 → Sep 9, 2016 · 2 filings
  • Sep 9, 2016 · D · $37,606,945 sold of $47,607,004 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 13, 2014 · D · $13,282,116 sold of $33,203,198 · 31 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $37.6M from 31 investors (79% of the $47.6M target) as of the latest filing. Wende is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BH
Manufacturing

Butterfly Health, Inc.

Los Gatos, CA · Sep 6, 2012 → May 8, 2015 · 4 filings
  • May 8, 2015 · D · $3,056,409 sold of $3,100,000 · 45 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 4, 2013 · D/A · $5,556,575 sold of $15,383,300 · 56 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 30, 2013 · D · $2,785,899 sold of $15,383,300 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 6, 2012 · D · $2,219,457 sold of $6,500,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5.56M from 56 investors (100% of the $3.1M target) as of the latest filing. Wende is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Manufacturing / 506(b) (1,339 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TS
Biotechnology

Theraclone Sciences, Inc.

Seattle, WA · Mar 17, 2010 → May 7, 2015 · 7 filings
  • May 7, 2015 · D · $3,080,000 sold of $4,408,149 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 29, 2013 · D/A · $6,000,000 sold of $6,396,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 29, 2013 · D · $6,000,000 sold of $6,396,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 26, 2013 · D · $4,000,000 sold of $8,000,001 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 23, 2011 · D/A · $11,584,603 sold of $11,584,603 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 12, 2011 · D · $10,584,603 sold of $10,584,603 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 17, 2010 · D · $1,500,000 sold of $1,500,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $11.6M from 18 investors (100% of the $4.41M target) as of the latest filing. Wende is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TM
Other Health Care

Transcend Medical Inc

Menlo Park, CA · May 28, 2009 → Jan 5, 2015 · 5 filings
  • Jan 5, 2015 · D/A · $29,267,917 sold of $29,267,917 · 18 investors · min. $1 · role: Director EDGAR ↗
  • Apr 2, 2014 · D · $21,999,994 sold of $22,499,994 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 14, 2011 · D · $27,571,426 sold of $27,571,428 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 20, 2009 · D/A · $23,428,572 sold of $41,000,001 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 28, 2009 · D · $19,999,999 sold of $40,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $29.3M from 18 investors (100% of the $29.3M target) as of the latest filing. Wende is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

D
Other Health Care

Dermira, Inc.

Menlo Park, CA · Sep 12, 2012 → Sep 30, 2014 · 3 filings
  • Sep 30, 2014 · D · $50,999,991 sold of $50,999,996 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 13, 2013 · D · $25,000,000 sold of $25,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 12, 2012 · D · $34,006,738 sold of $42,006,739 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $51M from 15 investors (100% of the $51M target) as of the latest filing. Wende is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Biotechnology

ALDEA Pharmaceuticals, Inc.

Redwood City, CA · Oct 6, 2011 → Aug 25, 2014 · 5 filings
  • Aug 25, 2014 · D · $9,262,658 sold of $24,058,143 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 18, 2013 · D/A · $11,380,718 sold of $11,483,692 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 8, 2012 · D/A · $4,513,491 sold of $7,382,620 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 15, 2012 · D/A · $1,277,000 sold of $1,277,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 6, 2011 · D · $1,027,000 sold of $1,027,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $11.4M from 6 investors (47% of the $24.1M target) as of the latest filing. Wende is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LB
Pharmaceuticals · group: Venbio

Labrys Biologics, Inc.

San Francisco, CA · Dec 28, 2012
  • Dec 28, 2012 · D · $14,588,234 sold of $30,999,997 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $14.6M from 5 investors (47% of the $31M target) as of the latest filing. Wende is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

A
Other

Altheos, Inc.

South San Francisco, CA · Jul 25, 2011 → Feb 23, 2012 · 2 filings
  • Feb 23, 2012 · D/A · $16,560,013 sold of $16,560,013 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 25, 2011 · D · $6,560,014 sold of $6,560,014 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $16.6M from 6 investors (100% of the $16.6M target) as of the latest filing. Wende is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

CM
Other Health Care

Calibra Medical, Inc.

Redwood City, CA · Nov 20, 2009 → Apr 14, 2011 · 4 filings
  • Apr 14, 2011 · D · $8,110,136 sold of $30,000,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 4, 2011 · D · $1,000,000 sold of $1,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 22, 2010 · D · $9,317,895 sold of $32,286,257 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 20, 2009 · D · $1,400,000 sold of $1,400,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $9.32M from 6 investors (31% of the $30M target) as of the latest filing. Wende is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

A
Other Health Care

Apieron Inc

Menlo Park, CA · Apr 7, 2009
  • Apr 7, 2009 · D · $5,924,643 sold of $16,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5.92M from 9 investors (37% of the $16M target) as of the latest filing. Wende is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Wende Hutton — OH, 1 issuer, Mar 3, 2015 → Nov 19, 2015 · no shared issuer

People around Wende 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

SG
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Gillis

Executive Officer, Director · 11 shared filings (2 issuers) · also on 28 other issuers

Steven Gillis is on 30 issuers in total — a repeat sponsor. Their page lists every one.

CS
No photo found yet (own website and image search run after this page is viewed)
Person

Clifford Stocks

Executive Officer, Director · 11 shared filings (2 issuers) · also on 4 other issuers

Clifford Stocks is on 6 issuers in total — a repeat sponsor. Their page lists every one.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Russ Hawkinson

Executive Officer · 10 shared filings (2 issuers)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

CM
No photo found yet (own website and image search run after this page is viewed)
Person

Christopher Mirabelli

Director · 7 shared filings (1 issuer) · also on 10 other issuers

Christopher Mirabelli is on 11 issuers in total — a repeat sponsor. Their page lists every one.

KS
No photo found yet (own website and image search run after this page is viewed)
Person

Kristine Swiderek

Executive Officer · 6 shared filings (2 issuers)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Timothy Shannon

Executive Officer, Director · 5 shared filings (1 issuer) · also on 9 other issuers

Timothy Shannon is on 10 issuers in total — a repeat sponsor. Their page lists every one.

RB
No photo found yet (own website and image search run after this page is viewed)
Person

Robert C. Bellas, Jr.

Director · 5 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Wende Hutton. Their page shows their other deals.

BW
No photo found yet (own website and image search run after this page is viewed)
Person

Brian Walsh

Executive Officer, Director · 5 shared filings (1 issuer) · also on 7 other issuers

Brian Walsh is on 8 issuers in total — a repeat sponsor. Their page lists every one.

JG
No photo found yet (own website and image search run after this page is viewed)
Person

Jim Glasheen

Director · 5 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Wende Hutton. Their page shows their other deals.

WY
No photo found yet (own website and image search run after this page is viewed)
Person

Wenjin Yang

Executive Officer · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Wende Hutton. Their page shows their other deals.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

David Stassen

Director · 5 shared filings (1 issuer) · also on 8 other issuers

David Stassen is on 9 issuers in total — a repeat sponsor. Their page lists every one.

NE
No photo found yet (own website and image search run after this page is viewed)
Person

Nathan Every

Director · 4 shared filings (1 issuer) · also on 28 other issuers

Nathan Every is on 29 issuers in total — a repeat sponsor. Their page lists every one.

BW
No photo found yet (own website and image search run after this page is viewed)
Person

Barbara Wirostko

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

BD
No photo found yet (own website and image search run after this page is viewed)
Person

Brian H. Dovey

Director · 4 shared filings (1 issuer) · also on 14 other issuers

Brian H. Dovey is on 15 issuers in total — a repeat sponsor. Their page lists every one.

WA
No photo found yet (own website and image search run after this page is viewed)
Person

William Albright

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

CA
No photo found yet (own website and image search run after this page is viewed)
Person

Clifton Alferness

Director · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

DE
No photo found yet (own website and image search run after this page is viewed)
Person

Dwayne Elwood

Director · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

JP
No photo found yet (own website and image search run after this page is viewed)
Person

Jeffrey Purvin

Executive Officer, Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Wende Hutton. Their page shows their other deals.

GM
No photo found yet (own website and image search run after this page is viewed)
Person

Gail Maderis

Executive Officer, Director · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Wende Hutton. Their page shows their other deals.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Randy Alexander

Executive Officer, Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Wende Hutton. Their page shows their other deals.

KR
No photo found yet (own website and image search run after this page is viewed)
Person

Karl P Ronn

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Wende Hutton. Their page shows their other deals.

WR
No photo found yet (own website and image search run after this page is viewed)
Person

Wendye Robbins

Director · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John P. McKearn

Director · 4 shared filings (1 issuer) · also on 16 other issuers

John P. McKearn is on 17 issuers in total — a repeat sponsor. Their page lists every one.

SJ
No photo found yet (own website and image search run after this page is viewed)
Person

Steven P. James

Director · 4 shared filings (2 issuers) · also on 3 other issuers

Steven P. James is on 5 issuers in total — a repeat sponsor. Their page lists every one.

WH
No photo found yet (own website and image search run after this page is viewed)
Person

William Harrington

Director · 4 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Wende Hutton. Their page shows their other deals.

SW
No photo found yet (own website and image search run after this page is viewed)
Person

Sarah Walter

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

David Myung

Director · 4 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

TH
No photo found yet (own website and image search run after this page is viewed)
Person

Thurein Htoo

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Ronald M. Hunt

Director · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Wende Hutton. Their page shows their other deals.

AD
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew Danielson

Director · 3 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

GK
No photo found yet (own website and image search run after this page is viewed)
Person

Gilbert H. Kliman

Director · 3 shared filings (1 issuer) · also on 6 other issuers

Gilbert H. Kliman is on 7 issuers in total — a repeat sponsor. Their page lists every one.

TW
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas G. Wiggans

Executive Officer, Director, Promoter · 3 shared filings (1 issuer) · also on 5 other issuers

Thomas G. Wiggans is on 6 issuers in total — a repeat sponsor. Their page lists every one.

AW
No photo found yet (own website and image search run after this page is viewed)
Person

Al Wiegman

Director · 3 shared filings (1 issuer) · also on 5 other issuers

Al Wiegman is on 6 issuers in total — a repeat sponsor. Their page lists every one.

RZ
No photo found yet (own website and image search run after this page is viewed)
Person

Reza Zadno

Director · 3 shared filings (1 issuer) · also on 8 other issuers

Reza Zadno is on 9 issuers in total — a repeat sponsor. Their page lists every one.

ED
No photo found yet (own website and image search run after this page is viewed)
Person

Eugene de Juan, Jr., M.D.

Director · 3 shared filings (1 issuer) · also on 4 other issuers

Eugene de Juan, Jr., M.D. is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JN
No photo found yet (own website and image search run after this page is viewed)
Person

Jake Nunn

Director · 3 shared filings (1 issuer) · also on 4 other issuers

Jake Nunn is on 5 issuers in total — a repeat sponsor. Their page lists every one.

RL
No photo found yet (own website and image search run after this page is viewed)
Person

Rich Lin

Director · 3 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

FC
No photo found yet (own website and image search run after this page is viewed)
Person

Fred Craves

Director · 3 shared filings (1 issuer) · also on 4 other issuers

Fred Craves is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Jay T. Holmes

Director · 3 shared filings (1 issuer)

Listed on the same filings as Wende Hutton. Their page shows their other deals.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Alain Schreiber

Director · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Wende Hutton. Their page shows their other deals.

The team behind the deals

V
Sponsor group

Venbio

7 issuers · 17 filings · $1.97B reported sold · 2010–2024

One team, 7 deal companies. Wende Hutton is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Wende Hutton.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 18 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Wende Hutton by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 18 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Wende Hutton is listed on: none on file. No website or social profile named in REVISION OPTICS INC's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #279,757 of 374,652 in line (1,376 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Lake Forest, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗Massachusetts MassCourts ↗Washington Courts case search (dw.courts.wa.gov) ↗Texas re:SearchTX court records ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗Massachusetts Secretary of State business search ↗Washington Secretary of State business search ↗Texas Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Wende Hutton appears on a new Form D, or when a court case or SEC action is matched to them. See plans →